[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"kidney-stone\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:kidney-stone":26},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,28,0,25,[9,40,72,100,124,146,175,191,215,240,264,285,312,334,353,375,400,421,442,463,490,514,537,557,581],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100515595","randomized-controlled-trial-of-miniaturized-percutaneous-nephrolithotomy-with-vacuum-assisted-access-sheaths-versus-conventional-sheaths-for-treatment-of-nephrolithiasis-100515595",false,"NCT05993546","Randomized Controlled Trial of Miniaturized Percutaneous Nephrolithotomy With Vacuum-Assisted Access Sheaths Versus Conventional Sheaths for Treatment of Nephrolithiasis","Inclusion Criteria:\n\n* Patients with planned prone mini-PCNL and a preoperative NCCT\n* Primary stone size: 10-25 mm\n* Pre-existing indwelling nephrostomy tube or ureteral stent permitted\n* Age: ≥ 18 years old\n* Gender: all\n* Ethnicity: all\n* Capable of giving informed consent\n* Capable and willing to fulfill requirements of the study\n\nExclusion Criteria:\n\n* Anticoagulated or history of coagulopathy\n* Congenital renal anomalies\n* Prior ipsilateral upper urinary tract reconstructive procedures\n* Conversion to open procedure\n* Multiple access tracts\n* Inability to give informed consent or unable to meet requirements of the study for any reason","ALL","18 Years",{"count":19,"type":20},90,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to compare two variations of the mini-PCNL procedure using either a vacuum-assisted sheath or standard sheath which are both used for the surgical treatment of kidney stones. Both procedure types are commonly used in the treatment of kidneys stones and they have been shown to be safe and effective in the treatment of stones similar in size and location to your own.",[26],"Kidney Stone","RECRUITING","2026-06-26",{"date":30,"type":31},"2026-06-29","ACTUAL",{"date":33,"type":31},"2023-08-29",{"date":35,"type":20},"2026-12",{"name":37,"class":38},"The Cleveland Clinic","OTHER",1,{"id":41,"slug":42,"hasResults":12,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":55,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":39},"100643475","multimodal-opioid-free-anesthesia-in-rirs-100643475","NCT07636070","Multimodal Opioid-Free Anesthesia in RIRS","Multimodal Opioid-Free Anesthesia in RIRS: A Comparison of Dexmedetomidine-Ketamine Combination Versus Conventional Opioid-Based Protocols","Inclusion Criteria:\n\nAged 18 to 65 years ASA physical status I or II ASA III patients with controlled and stable systemic disease (e.g., well-controlled hypertension or type 2 diabetes without end-organ damage) Scheduled for elective retrograde intrarenal surgery (RIRS) under laryngeal mask airway (LMA) Ability to provide written informed consent\n\nExclusion Criteria:\n\nBMI greater than 40 kg\u002Fm² Chronic opioid use Severe cardiovascular disease (uncontrolled arrhythmia, unstable angina, or ejection fraction below 40%) Significant respiratory disease (FEV1 below 60% predicted or oxygen-dependent COPD) Neuropsychiatric disorders Pregnancy Known allergy to any study drug Anticipated difficult airway (Mallampati III-IV, mouth opening less than 3 cm, or thyromental distance less than 6 cm) Requirement for conversion from LMA to endotracheal intubation Emergency cases Withdrawal of informed consent","65 Years",{"count":49,"type":20},60,[23],"The goal of this clinical trial is to evaluate whether a dexmedetomidine-ketamine based opioid-free anesthesia (OFA) protocol can provide effective analgesia compared to conventional fentanyl-based anesthesia in adult patients undergoing elective retrograde intrarenal surgery (RIRS). The main questions it aims to answer are:\n\nDoes opioid-free anesthesia reduce postoperative opioid consumption compared to fentanyl-based anesthesia? Does opioid-free anesthesia result in lower postoperative pain scores?\n\nResearchers will compare the dexmedetomidine-ketamine group to the fentanyl-based anesthesia group to see if opioid-free anesthesia reduces opioid requirements and improves recovery quality.\n\nParticipants will receive either a dexmedetomidine-ketamine based OFA protocol or conventional fentanyl-based anesthesia during surgery and will be monitored for pain, opioid consumption, and recovery outcomes postoperatively.",[26,53,54],"Retrograde Intrarenal Surgery (RIRS)","Postoperative Pain",[56,57,58,59,60,61],"Opioid-Free Anesthesia","Dexmedetomidine","Ketamine","Postoperative Analgesia","Multimodal Analgesia","Laryngeal Mask Airway","NOT_YET_RECRUITING","2026-06-04",{"date":65,"type":31},"2026-06-09",{"date":67,"type":20},"2026-06-01",{"date":69,"type":20},"2026-08-10",{"name":71,"class":38},"murat sahin",{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":39},"100639910","effects-of-virtual-reality-education-on-anxiety-and-learning-in-patients-undergoing-urolithiasis-surgery-100639910","NCT07620873","Effects of Virtual Reality Education on Anxiety and Learning in Patients Undergoing Urolithiasis Surgery","The Effects of Two-Tier Test-Based Virtual Reality Education on Anxiety, Knowledge, Self-Care Ability, and Cognitive Load in Patients Undergoing Urolithiasis Surgery","VR-URO","Inclusion Criteria:\n\n* Patients scheduled to undergo urolithiasis surgery with procedure codes 77026B, 77027B, 77028B, or 76016B.\n* Aged 18 years or older.\n* Conscious and mentally alert.\n* Able to communicate in Mandarin Chinese and read written text.\n* Able to understand and operate virtual reality equipment.\n\nExclusion Criteria:\n\n* Patients with current psychiatric disorders or substance abuse.\n* Patients with hearing or visual impairment.\n* Patients with visual dizziness, vertigo, or virtual reality motion sickness symptoms.\n* Patients who are unable to cooperate or unwilling to participate in the study.",{"count":19,"type":20},[23],"This randomized controlled trial aims to evaluate the effects of two-tier virtual reality-based preoperative education on anxiety, learning knowledge, self-care ability, and cognitive load in patients undergoing urolithiasis surgery. Participants will be randomly assigned to routine education, standard virtual reality education, or two-tier virtual reality education groups. Outcomes will be assessed using anxiety scales, knowledge questionnaires, self-care ability measures, and cognitive load assessments before and after the intervention.",[84,26,85],"Urolithiasis","Ureter Stones",[87,88,84,89,90,91],"Virtual Reality","Preoperative Education","Anxiety","Self-Care Ability","Cognitive Load",{"date":93,"type":31},"2026-06-02",{"date":95,"type":20},"2026-07",{"date":97,"type":20},"2027-05",{"name":99,"class":38},"Wei-Lin, Huang",{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":21,"phases":108,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":120,"leadSponsor":122,"locationsCount":4},"100640697","evaluation-of-renal-injury-after-rirs-using-shear-wave-elastography-100640697","NCT07615452","Evaluation of Renal Injury After RIRS Using Shear-Wave Elastography","Assessment of Renal Parenchymal Damage Following Retrograde Intrarenal Surgery Using Shear-Wave Elastography","Inclusion Criteria:\n\n* Age ≥18 years\n* Patients undergoing RIRS for renal stones\n* Stone size between \\\u003C 20 mm\n* Negative urine culture\n\nExclusion Criteria:\n\n* Active urinary tract infection\n* Congenital renal anomalies\n* Solitary kidney\n* Chronic kidney disease\n* Previous PCNL or open surgery\n* Ureteral stricture disease",{"count":49,"type":20},[23],"This study aims to evaluate changes in renal parenchyma following retrograde intrarenal surgery (RIRS) using shear-wave elastography. Renal elastography measurements will be performed in patients undergoing RIRS for kidney stones on the preoperative day, on the first postoperative day, and on the seventh postoperative day. Postoperative pain scores, perioperative outcomes, stone-free status and complications will also be assessed.",[26],[112,113,114,115],"Retrograde intrarenal surgery","Shear-wave elastography","Kidney injury","kidney stone","2026-05-31",{"date":118,"type":31},"2026-06-03",{"date":67,"type":20},{"date":121,"type":20},"2026-11",{"name":123,"class":38},"Cengiz Canakci, MD",{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":21,"phases":132,"briefSummary":133,"conditions":134,"keywords":135,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":4},"100395540","heterozygous-individuals-for-agxt-and-kidney-stones-100395540","NCT04430426","Heterozygous Individuals for AGXT and Kidney Stones","Inclusion Criteria:\n\n* at least 18 years of age\n* history of calcium oxalate stones\n* heterozygous mutation of the AGXT gene, as evidenced by results from the Invitae Nephrolithiasis Panel\n* willingness to comply with a controlled diet for five days\n\nExclusion Criteria:\n\n* pregnant individuals\n* individuals who are currently breast feeding",{"count":131,"type":20},4,[23],"This study seeks to examine the effects of a heterozygous mutation of the AGXT gene in a stone forming population on endogenous oxalate production. Participants will consume a controlled low-oxalate diet and provide blood and urine samples to measure the amount of oxalate in their bodies. Subjects will then be administered an intravenous (IV) load of glycolate, providing additional blood and urine samples afterwards to measure any increase in oxalate levels.",[26],[115,136],"oxalate","2026-05-28",{"date":139,"type":31},"2026-05-29",{"date":141,"type":20},"2026-07-01",{"date":143,"type":20},"2032-08-01",{"name":145,"class":38},"University of Alabama at Birmingham",{"id":147,"slug":148,"hasResults":12,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":153,"sex":16,"minAge":17,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":21,"phases":157,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":174},"100541567","gut-oxalate-absorption-in-calcium-oxalate-stone-disease-100541567","NCT06331546","Gut Oxalate Absorption in Calcium Oxalate Stone Disease","Gastrointestinal Oxalate Absorption in Calcium Oxalate Stone Disease","Inclusion Criteria:\n\n* age 18-70 yrs\n* Body Mass Index \\> 18.5 kg\u002Fm2\n* Normal fasting serum electrolytes on comprehensive metabolic profile\n* Willing to ingest fixed diets\n* Willing to stop supplements (vitamins including vitamin C, calcium (citrate or carbonate) and other minerals, herbal supplements, nutritional aids, probiotics) for 2 weeks before start and during study.\n* For stone formers: first time or recurrent Calcium Oxalate stone former. Composition of most recent stone ≥ 50% calcium oxalate if available, uric acid component \\\u003C20%\n\nExclusion Criteria:\n\n* Chronic Kidney Disease stage 4-5\n* Primary hyperoxaluria, Enteric (secondary) hyperoxaluria\n* Liver, bowel, endocrine or renal diseases (other than idiopathic Calcium Oxalate kidney stones) or any other condition that may influence the absorption, transport or urinary excretion of ions, which will compromise the interpretation of results, including: Cystic fibrosis, Celiac disease, Cystinuria, Uric acid stone former, Nephrotic syndrome, Sarcoidosis, Renal tubular acidosis, Primary hyperparathyroidism, Neurogenic bladder, Urinary diversion, Chronic diarrhea, Bariatric surgery, Inflammatory bowel disease\n* Pregnancy or breast-feeding\n* Incompatible dietary requirements with the study, food allergies or intolerance to any of the foods in study menus\n* Active malignancy or treatment for malignancy within 12 months prior to screening\n* Utilization of immunosuppressive medication\n* Uncontrolled hypertension or diabetes\n* Diabetes type 1\n* Chronic NSAID use",true,"70 Years",{"count":156,"type":20},80,[23],"The goal of this clinical trial study is to test if patients with idiopathic calcium oxalate kidney stones have an increased absorption of dietary oxalate, which would lead to increased urinary excretion of oxalate.\n\nThe study will recruit adult patients with a history of calcium oxalate kidney stones and healthy volunteers without kidney stones.\n\nParticipants will\n\n* ingest fixed diets containing low and moderately high amounts of oxalate for 5 days at a time\n* ingest a soluble form of oxalate and sugar preparations to test gut permeability\n* collect urine, blood, stool and breath sample during the fixed diets and the soluble oxalate test",[26,160,84,161,162,163,164,165,166],"Kidney Calculi","Urolithiasis, Calcium Oxalate","Nephrolithiasis","Nephrolithiasis, Calcium Oxalate","Oxalate Urolithiasis","Oxaluria","Healthy","2026-05-27",{"date":137,"type":31},{"date":170,"type":31},"2024-04-17",{"date":172,"type":20},"2031-12-31",{"name":145,"class":38},2,{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":154,"enrollmentInfo":182,"targetDuration":4,"studyType":21,"phases":184,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":187,"startDateStruct":188,"completionDateStruct":189,"leadSponsor":190,"locationsCount":174},"100541467","o-formigenes-colonization-in-calcium-oxalate-kidney-stone-disease-100541467","NCT06330246","O. Formigenes Colonization in Calcium Oxalate Kidney Stone Disease","Oxalobacter Formigenes Colonization in Calcium Oxalate Kidney Stone Formers","Inclusion Criteria\n\n* age 19-70 yrs\n* Body Mass Index \\> 18.5 kg\u002Fm2\n* First time or recurrent Calcium Oxalate stone former. Composition of most recent stone ≥ 50% calcium oxalate if available\n* Not colonized with Oxalobacter formigenes\n* Normal fasting serum electrolytes on comprehensive metabolic profile\n* Willing to ingest fixed diets\n* Willing to stop supplements (vitamins including vitamin C, calcium (citrate or carbonate) and other minerals, herbal supplements, nutritional aids, probiotics) for 2 weeks before start and during fixed diet phases.\n* If on medications for stone prevention (e.g. thiazides, citrate, allopurinol), stable dose regimen for at least 2 weeks prior to and during study\n\nExclusion Criteria\n\n* Chronic Kidney Disease stage 4-5\n* Primary hyperoxaluria\n* Liver, endocrine or renal diseases (other than idiopathic Calcium Oxalate kidney stones) or any other condition that may influence the absorption, transport or urinary excretion of ions, which will compromise the interpretation of results, including: Cystic fibrosis, Cystinuria, Uric acid stone former, Nephrotic syndrome, Sarcoidosis, Renal tubular acidosis, Primary hyperparathyroidism, Neurogenic bladder, Urinary diversion\n* Pregnancy or breast-feeding\n* Incompatible dietary requirements with the study, food allergies or intolerance to any of the foods in study menus\n* Active malignancy or treatment for malignancy within 12 months prior to screening\n* Utilization of immunosuppressive medication\n* Uncontrolled Hypertension or diabetes\n* Diabetes type 1\n* Current Colonization with Oxalobacter formigenes",{"count":183,"type":20},40,[23],"The goal of this trial is to test if colonization with the gut bacteria Oxalobacter formigenes leads to a reduction in urinary oxalate excretion in patients with calcium oxalate kidney stone disease.\n\nThe study will recruit adult participants with a history of calcium oxalate kidney stones who are not colonized with Oxalobacter formigenes.\n\nParticipants will\n\n* ingest fixed diets containing low and moderately high amounts of oxalate for 4 days at a time\n* collect urine, blood and stool samples during the fixed diets\n* ingest a preparation of live Oxalobacter formigenes to induce colonization with Oxalobacter formigenes",[26,160,84,161,162,163,164,165],{"date":137,"type":31},{"date":170,"type":31},{"date":172,"type":20},{"name":145,"class":38},{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":21,"phases":201,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":214},"100566327","phase-3-trial-to-assess-the-efficacy-of-empagliflozin-and-personalized-dietary-counseling-for-kidney-stone-prevention-100566327","NCT06653738","Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention","Randomized Placebo-controlled Trial to Assess Efficacies of EMPAgliflozin and Personalized Dietary Counselling for Kidney STONE Prevention in Patients With Calcium Kidney Stones Acronym: EMPASTONE Trial","EMPASTONE","Inclusion criteria:\n\n1. Written, informed consent.\n2. Age 18 years or older.\n3. Recurrent kidney stone disease with 2 or more stone episodes in the last 10 years prior to randomization.\n4. Last kidney stone containing 50% or more of CaOx, CaP or a mixture of both.\n5. If taking guideline-recommended medications for kidney stone prophylaxis (e.g. citrate salts), patients must have been on a stable regimen for at least 60 days before randomization and willing to remain on this stable regimen for the duration of the study.\n\nExclusion criteria:\n\n1. Known history of secondary or Mendelian causes of calcium nephrolithiasis\n2. Type I diabetes mellitus\n3. History of ketoacidosis\n4. Chronic Kidney Disease (CKD) stage 4 or 5 (defined as CKD-EPI eGFR \\\u003C30 mL\u002Fmin)\n5. Kidney transplant recipient\n6. History of recurrent urinary tract infections, defined as \\>3 episodes within the year prior to randomization\n7. Heart failure. Symptomatic patients with suspected heart failure must be evaluated before study enrollment\n8. Treatment with an SGLT2i within 4 weeks prior to randomization.\n9. Active cancer treatment\n10. Pregnancy and\u002For breastfeeding. Women of childbearing potential (i.e., premenopausal women who have not undergone surgical sterilization and are sexually active with a male partner) must have a negative urine or blood pregnancy test prior to enrollment\n11. Known allergy to the study drug\n12. Inability to understand and follow the study procedures\n13. Vulnerable individual, e.g. individual incapable of judgement or currently incarcerated or otherwise institutionalized (priosner), or refugee\n14. Concomitant participation in another interventional clinical trial within 4 weeks prior to randomization and during the current trial\n15. Prior enrollment in the EMPASTONE trial",{"count":200,"type":20},400,[202],"PHASE3","The aim of this randomized trial with a 2-by-2 factorial design is to test the efficacy of the SGLT2 inhibitor empagliflozin and personalized dietary counseling based on 24-hr urine collection results and dietary assessments for kidney stone recurrence prevention in patients with calcium kidney stones.\n\nStudy interventions:\n\n* Empagliflozin 10 mg once daily per os for 36 months\n* Personalized dietary counseling for 36 months.\n\nControl interventions:\n\n* Placebo once daily per os for 36 months\n* Generic dietary counseling for 36 months.",[26,162,205],"Dietary Exposure","2026-05-21",{"date":167,"type":31},{"date":209,"type":20},"2026-06",{"date":211,"type":20},"2030-09",{"name":213,"class":38},"Insel Gruppe AG, University Hospital Bern",21,{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":223,"enrollmentInfo":224,"targetDuration":4,"studyType":21,"phases":226,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":174},"100578732","a-novel-ureteric-stent-in-kidney-stone-patients-and-oncology-patients-compared-to-a-conventional-jj-stent-100578732","NCT06815120","A Novel Ureteric Stent in Kidney Stone Patients and Oncology Patients Compared to a Conventional JJ Stent","Two Single Arm, Multicentre Unblinded First-in-human Trials Investigating a Novel Ureteric Stent to Determine the Reduction of Encrustation, Biofilm Deposition and Complications Compared to a Conventional JJ Stent","CASSETTE","Inclusion Criteria:\n\n1. Aged 18 years or over\n2. Ureteric stents clinically indicated either due to kidney stones or abdominal\u002Fpelvic cancers compressing ureters\n3. Previous experience with ureteric stents\n4. Awaiting insersion\u002Freplacement of stents\n5. Ability to give consent\n6. Ability to interact with study documentation\n7. Sufficient English to complete study documentations and questionnaires\n\nExclusion Criteria:\n\n1. Expected survival \\\u003C4months\n2. Unfit for stent insertion\n3. Unable to comply with study processes Pregnancy","99 Years",{"count":225,"type":20},50,[23],"Urological stents and catheters often lead to inflammation, causing pain and infection in the urinary tract. Moreover, 80% of stents are associated with pain, negatively impacting on QoL and mental health. Offering novel designs with significantly lower E\\&B leads to a reduction in UTIs and improves QoL. Reducing hospital admissions (from 3 to 1 per patient, annually) would free \\>100,000 bed-nights, allowing the elderly to regain independence. Our proposed research could have a significant impact towards fulfilling the 'healthy-ageing' Grand Challenge. Additionally, the novel stent reduces prevalence of infections and therefore, of antibiotic prescriptions contributing to the Global AMR challenge.",[229,230,26],"Catheter Blockage","Oncology","2026-05-06",{"date":233,"type":31},"2026-05-11",{"date":235,"type":31},"2025-08-06",{"date":237,"type":20},"2026-12-31",{"name":239,"class":38},"University of Southampton",{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":21,"phases":249,"briefSummary":250,"conditions":251,"keywords":252,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":39},"100599706","hoyag-vs-tfl-in-minipcnl-with-clearpetra-100599706","NCT07087977","HoYAG vs TFL in miniPCNL With ClearPetra","Holmium:YAG Laser With MOSES Technology vs Thulium Fiber Laser in Supine Mini-percutaneous Nephrolithotomy With Vacuum-assisted Renal Access Sheath: A Prospective, Randomized Clinical Trial","Inclusion Criteria:\n\n1. Males or females over 18 years of age\n2. Patients with kidney stones, with stone burden larger than 15 mm.\n3. Patients undergoing new percutaneous access with primary, supine, unilateral mini-PCNL.\n\n   Exclusion Criteria:\n4. Simultaneous use of more than 1 laser platform or other form of fragmentation (e.g., ultrasonic).\n5. Patients undergoing simultaneous treatment of contralateral kidney stones during the same procedure.\n6. Patients undergoing simultaneous treatment of ureteral stones during the same procedure.\n7. Pregnant patients.\n8. Presence of genitourinary anatomical abnormalities.\n9. Uncorrected coagulopathy.\n10. External urinary catheters.\n11. Immunosuppressed patients.\n12. Non-elective procedures.",{"count":248,"type":20},150,[23],"Mini percutaneous nephrolithotripsy is the treatment of choice for kidney stones over 2cm. This procedure commonly uses laser energy for breaking the stones, and among possible laser platforms, Hoyag and thulium fiber laser are FDA approved. Recently, this procedure has also included the use of vacuum assisted renal access sheaths, which allows suction to be employed together with the breaking of stones. This study intends to compare outcomes when using either laser platforms with suction sheaths in participants undergoing mini percutaneous nephrolithotripsy for the treatment of kidney stones.",[162,26],[162,26,253,254,255],"ClearPetra","HoYAG","TFL","2026-05-01",{"date":231,"type":31},{"date":259,"type":31},"2025-08-22",{"date":261,"type":20},"2027-12-01",{"name":263,"class":38},"University of Kansas Medical Center",{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":153,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":21,"phases":272,"briefSummary":273,"conditions":274,"keywords":275,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":39},"100560401","evaluation-of-the-lithovue-elite-ureteroscope-with-intra-renal-pressure-monitoring-technology-examination-of-surgeon-behavior-and-post-operative-outcomes-100560401","NCT06576661","Evaluation of the LithoVue Elite Ureteroscope With Intra-Renal Pressure Monitoring Technology: Examination of Surgeon Behavior and Post-operative Outcomes","ELITE","Inclusion Criteria:\n\n* Males or females over 18 years of age\n* Undergoing flexible ureteroscopy to address urinary stones located in the proximal ureter or kidney\n* Total stone burden over 2 cm\n\nExclusion Criteria:\n\n1. Undergoing bilateral stone treatment during the same procedure\n2. Patients with known genitourinary anatomical abnormalities\n3. Uncorrected coagulopathy\n4. Patients with urinary diversions\n5. Chronic external urinary catheters\n6. Women who are pregnant\n7. Immunosuppressed patients",{"count":156,"type":20},[23],"The goal of this study is to evaluate the influence of real-time intrarenal pressure measurement availability on surgeons' behavior during ureteroscopy while using the ureteroscope LithoVue Elite.",[26,162],[276,277],"Intrarenal Pressure","LithoVue Elite",{"date":279,"type":31},"2026-05-04",{"date":281,"type":31},"2025-01-28",{"date":283,"type":20},"2026-11-01",{"name":263,"class":38},{"id":286,"slug":287,"hasResults":12,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":291,"eligibilityCriteria":292,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":21,"phases":295,"briefSummary":297,"conditions":298,"keywords":299,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":39},"100524680","phase-2-indapamide-and-chlorthalidone-to-reduce-urine-supersaturation-for-kidney-stone-prevention-100524680","NCT06111885","Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Kidney Stone Prevention","Randomized, Double-blind, Crossover Trial Assessing the Efficacy of Indapamide and Chlorthalidone Compared to Hydrochlorothiazide for the Reduction of Urine Supersaturation for Kidney Stone Prevention","INDAPACHLOR","Inclusion criteria:\n\n* Written, informed consent.\n* Age 18 years or older.\n* Recurrent kidney stone disease (≥2 kidney stone episodes in the last 10 years prior to randomisation).\n* Past kidney stone containing ≥50 % CaOx, CaP, or a mixture of both.\n\nExclusion criteria:\n\n* Patients with secondary causes of recurrent calcium kidney stones including severe eating disorders (anorexia or bulimia), chronic bowel disease, intestinal or bariatric surgery, sarcoidosis, primary hyperparathyroidism, chronic urinary tract infection.\n* Patients with the following medications: Thiazide or loop diuretics, carbonic anhydrase inhibitors (including topiramate), xanthine oxidase inhibitors, alkali, active vitamin D (calcitriol or similar), calcium supplementation, bisphosphonates, denusomab, teriparatide, sodium-glucose co-transporter 2 (SGLT2) inhibitors, strong CYP3A4 inhibitors or inducers (may affect indapamide metabolism), lithium (To be eligible for study participation, patients taking any of the above listed medications at screening must be willing to discontinue these medications at least 28 days before randomization).\n* Patients with chronic kidney disease (defined as CKD-EPI eGFR \\\u003C30 mL\u002Fmin).\n* Patients with glomerulonephritis.\n* Patients with the following biochemical imbalances: severe hypercalcemia (\\>2.8 mmol\u002FL), therapy-resistant hypokalemia or conditions with increased potassium loss, severe hyponatremia (\\\u003C130 mmol\u002FL), symptomatic hyperuricemia.\n* Patients with hepatic encephalopathy or severe liver insufficiency.\n* Patients with severe cardiac insufficiency.\n* Patient with a recent cerebrovascular event.\n* Patients with a solid organ transplant.\n* Pregnant and lactating women (A urine pregnancy test must be performed for women of child-bearing potential, defined as women who are not surgically sterilized\u002Fhysterectomized, and\u002For who are postmenopausal for less than 12 months).\n* Previous (within 3 months prior to randomization) or concomitant participation in another interventional clinical trial.\n* Previous participation in INDAPACHLOR.\n* Inability to understand and follow the protocol.\n* Allergy to any one of the study drugs.",{"count":294,"type":20},99,[296],"PHASE2","The aim of this study is to test the efficacy of the two long-acting thiazide-like diuretics indapamide and chlorthalidone in reducing urine supersaturation for calcium oxalate and calcium phosphate compared to the short-acting thiazide diuretic hydrochlorothiazide for the prevention of calcium-containing kidney stones.",[26],[162,300,301,302,303,304],"Kidney stones","Thiazide","Hydrochlorothiazide","Indapamide","Chlorthalidone","2026-04-30",{"date":231,"type":31},{"date":308,"type":31},"2024-10-01",{"date":310,"type":20},"2027-06-30",{"name":213,"class":38},{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":319,"enrollmentInfo":320,"targetDuration":4,"studyType":21,"phases":322,"briefSummary":323,"conditions":324,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":39},"100636176","safety-and-efficacy-of-combination-of-tamsulosin-04-mg-plus-tadalafil-5mg-versus-25-mg-100636176","NCT07562282","Safety and Efficacy of Combination of Tamsulosin 0.4 mg Plus Tadalafil 5mg Versus 2.5 mg","Safety and Efficacy of Combination of Tamsulosin 0.4 mg Plus Tadalafil 5mg Versus 2.5 mg for Ureteric Stent Related Symptoms","Inclusion Criteria:\n\n\\- patients older than 18 years of age, with presence of a double-J (DJ) stent (polyurethane) post endoscopic stone removal.\n\nExclusion Criteria:\n\n* Patients younger than 18 years of age were excluded.\n* Patients with a history of prostate or bladder surgery were excluded.\n* Patients with prior lower urinary tract procedures were excluded.\n* Patients with cancer were excluded.\n* Patients with neurological conditions were excluded.\n* Patients with a history of pelvic radiation were excluded.\n* Patients with diabetes were excluded.\n* Patients with kidney dysfunction (acute or chronic) were excluded.\n* Patients with a solitary kidney were excluded.\n* Patients with congenital urinary anomalies were excluded.\n* Patients taking the following medications were excluded:\n\n  * α-blockers\n  * beta-blockers\n  * calcium channel blockers\n  * 5-alpha reductase inhibitors\n  * PDE5 inhibitors\n  * anticholinergics\n  * nitrates\n* Patients with cardiac issues were excluded.\n* Patients with residual stone fragments after surgery were excluded.\n* Patients with multiple or bilateral ureteral stones were excluded.\n* Patients with long-term or bilateral stents requiring frequent changes were excluded.\n* Patients with interstitial cystitis were excluded.\n* Patients with chronic cystitis were excluded.\n* Patients with prostatitis were excluded.\n* Pregnant women were excluded.\n* Breastfeeding women were excluded.\n* Patients unavailable for follow-up were excluded.","71 Years",{"count":321,"type":20},140,[23],"Ureteral stenting is a common urological procedure performed to relieve obstruction and facilitate urinary drainage. Despite its effectiveness, stent-related symptoms (SRS) such as dysuria, frequency, urgency, flank pain, and sexual discomfort negatively affect patient quality of life.\n\nPharmacological management with alpha-blockers such as Tamsulosin and phosphodiesterase-5 inhibitors (PDE5i) such as Tadalafil has shown promise in reducing SRS. While low-dose Tadalafil (2.5 mg) has not been explored, its comparative effectiveness against the standard 5 mg dose when combined with Tamsulosin remains under-researched. This study aims to evaluate the difference in reduction of SRS between Tamsulosin with Tadalafil in standard and half dosage.",[26,325],"Ureteric Stone","2026-04-25",{"date":256,"type":31},{"date":329,"type":31},"2025-12-01",{"date":331,"type":20},"2026-07-10",{"name":333,"class":38},"Ain Shams University",{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":4,"eligibilityCriteria":340,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":341,"targetDuration":4,"studyType":21,"phases":343,"briefSummary":344,"conditions":345,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":350,"leadSponsor":351,"locationsCount":174},"100632624","prospective-multi-center-study-comparing-pulsed-tmyag-laser-to-pulse-modulated-holmium-laser-in-the-treatment-of-nephrolithiasis-with-fans-access-sheaths-100632624","NCT07516106","Prospective Multi-center Study Comparing Pulsed Tm:YAG Laser to Pulse Modulated Holmium Laser in the Treatment of Nephrolithiasis With FANS Access Sheaths","Prospective Multi-center Study Comparing Pulsed Tm:YAG Laser to Pulse Modulated Holmium Laser in the Treatment of Nephrolithiasis With Flexible And Navigable Ureteric Access Sheath (FANS)","Inclusion Criteria:\n\n* Solitary renal stone 7 to 20 mm in size or in the case of multiple stones the conglomerate diameter (additive maximal diameter of all stones on axial imaging of computed tomography) of 7-20 mm is required\n* Must be a suitable operative candidate for flexible ureteroscopy per American Urological Association guidelines\n* Must be 18 years or older\n* Must be able to give consent\n* Bilateral ureteroscopy will be permitted , but only the side(s) where the FANS access sheath was used (per surgeon discretion) will be included in the study, however can include both sides as separate units. Subjects will be enrolled only once in the study. No subject will be enrolled more than a single time. For patients undergoing bilateral ureteroscopy, each kidney will be considered a separate unit for stone-related assessments. Peri-patient measures, such as operative time, will be recorded at the patient level. Bilateral cases will be clearly identified and handled consistently to ensure accurate and appropriate interpretation of study outcomes.\n* Must be a patient of one of the surgeons participating in this study.\n\nExclusion Criteria:\n\n* Concomitant stones in the ureter\n* Prior radiotherapy to the abdomen or pelvis\n* Neurogenic bladder or spinal cord injury\n* Pregnancy\n* Untreated urinary tract infection (UTI)\n* Anatomical abnormalities (including, but not limited to, bifid system, pelvic kidney, horseshoe kidney)\n* Prior ipsilateral upper urinary tract reconstructive procedures or history of ipsilateral ureteral stricture",{"count":342,"type":20},70,[23],"The purpose of this study is to compare two laser technologies that are routinely used during ureteroscopy for the treatment of kidney stones. Specifically, this study will compare a pulsed Thulium:YAG laser to a pulse-modulated Holmium:YAG laser (Moses technology) to evaluate how effective and safe they are when used to break kidney stones.\n\nPrimary endpoints include stone-free rate and the zero stone-free rate at a standardized postoperative. Secondary endpoints include total operative time, lasing time (s), laser energy expended (J), efficiency (laser energy expended\u002Fstone volume; stone volume\u002Flasing time). These endpoints aim to provide a comprehensive assessment of the clinical effectiveness and procedural efficiency of the two laser systems.",[26],"2026-03-31",{"date":348,"type":31},"2026-04-07",{"date":209,"type":20},{"date":310,"type":20},{"name":352,"class":38},"NYU Langone Health",{"id":354,"slug":355,"hasResults":12,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":153,"sex":16,"minAge":17,"maxAge":360,"enrollmentInfo":361,"targetDuration":4,"studyType":21,"phases":363,"briefSummary":365,"conditions":366,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":371,"leadSponsor":373,"locationsCount":39},"100412479","early-phase-1-comparing-alkalinizing-agents-efficacy-on-stone-risk-in-patients-on-a-metabolically-controlled-diet-100412479","NCT04651088","Comparing Alkalinizing Agents Efficacy on Stone Risk in Patients on a Metabolically Controlled Diet","Evaluation of Multiple Alkalinizing Agents on Urinary Stone Risk Parameters in Stone and Non-stone Formers on a Metabolically Controlled Diet","Inclusion Criteria:\n\n* Adults aged 18 and older.\n* with or without a history of stone disease.\n\nExclusion Criteria:\n\n* They are unable to take any of the medications due to health reasons.\n* Participants are pregnant or nursing.\n* Participants are unable to adhere to the metabolic diet.\n* Participants had a prior adverse event from one or more of the medications.","90 Years",{"count":362,"type":20},15,[364],"EARLY_PHASE1","The purpose of this study is to compare over the counter and alternative prescription urinary alkalinizing agents to slow release potassium citrate in their ability to modify urinary parameters associated with stone formation.",[26],"2026-02-10",{"date":369,"type":31},"2026-02-13",{"date":141,"type":20},{"date":372,"type":20},"2027-07",{"name":374,"class":38},"University of Texas Southwestern Medical Center",{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":16,"minAge":382,"maxAge":383,"enrollmentInfo":384,"targetDuration":4,"studyType":21,"phases":386,"briefSummary":387,"conditions":388,"keywords":389,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":39},"100532223","effect-of-a-dash-style-diet-on-urinary-risk-factors-for-kidney-stone-disease-100532223","NCT06210009","Effect of a DASH-Style Diet on Urinary Risk Factors for Kidney Stone Disease","Effect of a DASH-Style Diet on Urinary Risk Factors for Kidney Stone Disease: A Randomized Controlled Trial (CARDIA Ancillary Study)","Inclusion Criteria:\n\n* Birmingham, AL area participants of the Coronary Artery Risk Development in Young Adults (CARDIA) study OR patients of the University of Alabama at Birmingham\u002FKirklin Clinic\n* Self-reported, documented, and\u002For prior imaging-based diagnosis of kidney stone disease\n* Age 19-89\n* Any sex\n* Any race\n* Able to provide informed consent\n* Willing to perform 24-hour urine collections\n* Willing to consume meals prepared by Bionutrition Unit\n* No food allergies\u002Fintolerance to any of the foods in the study menus\n* Willing to stop for 7 days before and during study: Multivitamins and\u002For Dietary supplements (including calcium and vitamin C)\n\nExclusion Criteria:\n\n* Dialysis\n* Kidney transplant recipient\n* Estimated glomerular filtration rate (eGFR) \\\u003C60 ml\u002Fmin\u002F1.73m2 based on historical laboratory measurements\n* Renal tubular acidosis\n* Current use of acetazolamide, topiramate, or zonisamide\n* Primary hyperparathyroidism or history of parathyroidectomy\n* Hyperthyroidism\n* Sarcoidosis\n* Primary hyperoxaluria\n* Cystinuria\n* Nephrotic syndrome\n* Malabsorptive conditions including inflammatory bowel disease or history of malabsorptive surgery (e.g., Roux-en-Y gastric bypass, small bowel resection)\n* Urinary retention requiring catheterization\n* Urinary diversion\n* Pregnancy\n* Breastfeeding\n* Malignancy treated in the past 12 months other than non-melanoma skin cancer","19 Years","89 Years",{"count":385,"type":20},48,[23],"The true capacity for a healthy diet to improve urinary stone risk factors is not well-defined. The objective of this study is to measure the effect of adopting a healthy dietary pattern on kidney stone disease (KSD) risk. The working hypothesis is that a Dietary Approaches to Stop Hypertension (DASH)-style diet will improve 24-hour urine stone risk parameters. The approach to testing this hypothesis will be to randomize participants with KSD to a standardized DASH-style vs. Western-style diet for one week. The Bionutrition Unit of the Center for Clinical and Translational Science will provide all meals to participants. The rationale for this study is that by measuring the effect of a DASH-style diet on urinary stone risk parameters, a benchmark for future real-world, implementation studies will be established. Based on available evidence, this will be the first controlled diet study to assess the DASH dietary pattern for improving urinary stone risk parameters.",[26],[390,391],"DASH diet","Western diet","2026-01-12",{"date":394,"type":31},"2026-01-13",{"date":396,"type":31},"2025-01-06",{"date":398,"type":20},"2027-08-31",{"name":145,"class":38},{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":153,"sex":16,"minAge":17,"maxAge":154,"enrollmentInfo":407,"targetDuration":4,"studyType":21,"phases":408,"briefSummary":409,"conditions":410,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":419,"locationsCount":39},"100464998","oxalate-and-citrate-100464998","NCT05334979","Oxalate and Citrate","Oxalate and Citrate in Humans","Inclusion Criteria:\n\nStone formers:\n\n* Age 18-70\n* History of at least one calcium-based kidney stone\n\nNon-stone formers (controls):\n\n* Age 18-70\n* No history of kidney stone\n* 24-hour urine oxalate within lab normal (\\\u003C50mg\u002Fday)\n\nExclusion Criteria:\n\n* History of primarily uric acid, cysteine, or struvite stones.\n* History of severe acid-base abnormality, very low (less than 100mg\u002Fday) or very high (greater than 1500mg\u002Fday) urine citrate.\n* Any controls or stone-forming participants who cannot stop diuretic medication or alkali supplementation for the course of the study period.\n* Non-stone formers and stone-formers with extreme levels of urine citrate will be excluded from this small initial study to reduce heterogeneity and remove focus from the extremes of citrate levels.",{"count":225,"type":20},[23],"This is a single-center study that aims to earn more about how two different compounds found in food, oxalate and citrate, may affect a person's chances of forming kidney stones.",[26,411],"Normal Controls","2026-01-07",{"date":414,"type":31},"2026-01-08",{"date":416,"type":31},"2022-10-27",{"date":418,"type":20},"2026-12-01",{"name":420,"class":38},"University of Chicago",{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":425,"acronym":4,"eligibilityCriteria":426,"healthyVolunteers":153,"sex":16,"minAge":17,"maxAge":154,"enrollmentInfo":427,"targetDuration":4,"studyType":21,"phases":429,"briefSummary":430,"conditions":431,"keywords":432,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":39},"100588655","oxalate-and-citrate-in-humans---response-to-citrate-100588655","NCT06944223","Oxalate and Citrate in Humans - Response to Citrate","Inclusion Criteria:\n\nStone formers (SF):\n\n* Age 18-70\n* History of at least one calcium-based kidney stone\n\nNon-stone formers (NSF):\n\n* Age 18-70\n* No history of kidney stone\n* 24-hour urine oxalate within laboratory normal range (\\\u003C50 mg\u002Fday)\n\nExclusion Criteria:\n\nHistory of primarily uric acid, cysteine, or struvite stones\n\nHistory of severe acid-base abnormality, very low (less than 100 mg\u002Fday) or very high (greater than 1500 mg\u002Fday) urine citrate\n\nAny controls or stone former (SF) participants who cannot stop diuretic medication or alkali supplementation for the course of the study period\n\nChronic kidney disease (glomerular filtration rate \\\u003C75 milliliters per minute per 1.73 square meters \\[mL\u002Fmin\u002F1.73 m²\\])\n\nNon-stone formers (NSF) and stone formers (SF) with extreme levels of urine citrate will be excluded from this small initial study to reduce heterogeneity and remove focus from the extremes of citrate levels.",{"count":428,"type":20},24,[23],"This is a single-center study that aims to learn more about how two compounds found in food, oxalate and citrate, interact in the body and may influence a person's chances of forming kidney stones. The study will examine changes in urinary oxalate and citrate levels after participants consume potassium citrate.",[26,166],[115,433],"kidney stones","2025-12-15",{"date":436,"type":31},"2025-12-16",{"date":438,"type":31},"2025-10-01",{"date":440,"type":20},"2027-06-01",{"name":420,"class":38},{"id":443,"slug":444,"hasResults":12,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":4,"eligibilityCriteria":448,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":449,"targetDuration":4,"studyType":21,"phases":451,"briefSummary":452,"conditions":453,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":39},"100334793","early-phase-1-nsaids-stent-study-100334793","NCT03638999","NSAIDs Stent Study","A Prospective, Randomized, Pilot Study of Preoperative Anti-Inflammatory Therapy for Ureteral Stent Symptoms","Inclusion Criteria:\n\n* Over 18 years of age and willing and able to provide informed consent\n* Patients with renal urolithiasis planning to undergo ureteral stent placement following ureteroscopic manipulation\n\nExclusion Criteria:\n\n* Patients requiring a bilateral stone procedure.\n* Patients on a chronic non-steroidal anti-inflammatory drugs (NSAIDs) including Aspirin defined as any NSAIDs use for more than fifteen days within thirty days prior to the procedure. Exception: use of daily Aspirin 81 mg is allowed.\n* Patients on any steroid therapy.\n* Patients with prescription anti-inflammatory drugs.\n* Patients with gastrointestinal ulcers.\n* Patients with ureteral obstruction or stricture unrelated to stone disease.\n* Patients with active urinary tract infection as evidence of untreated positive urine culture obtained prior to the procedure (as part of pre-operative testing).\n* Patients with preexisting indwelling ureteral stent\n* Patients who are pregnant or lactating.\n* Patients with renal or liver impairment.\n* Patients with concurrent disease, infection, or co-morbidity that, in the judgment of the investigator, would render the patient inappropriate for enrollment.",{"count":450,"type":20},36,[364],"This is a pilot study to (1) evaluate the effect of Ketorolac on inflammatory response and its impact on stent related symptoms in patients undergoing stent placement procedure and (2) assess feasibility of recruitment, randomization, assessment procedures and implementation of the study intervention.",[454,26],"Ureteral Stent Placement",{"date":456,"type":31},"2025-12-22",{"date":458,"type":31},"2018-07-31",{"date":460,"type":20},"2027-10",{"name":462,"class":38},"Washington University School of Medicine",{"id":464,"slug":465,"hasResults":12,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":469,"eligibilityCriteria":470,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":21,"phases":473,"briefSummary":474,"conditions":475,"keywords":477,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":39},"100615849","access-sheath-and-stent-trial-100615849","NCT07297953","Access Sheath and Stent Trial","Access Sheath and stENT Trial","ACCENT","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Planned ureteroscopy using a Ureteral Access Sheath (UAS) for treatment of unilateral kidney and\u002For ureteral stones in patients that have an existing ureteral stent (pre-stented)\n* Planned treatment of unilateral renal and\u002For ureteral stones, in a single procedure.\n* Renal stone defined as only renal location of stone(s)\n* Ureteral stone defined as ureteral only location of stone(s)\n* Ureteral and renal stone(s)\n* No evidence of significant ureteral injury on intra-operative assessment (Post-Ureteroscopy Lesion Scale (PULS) Grade 0 or 1)\n* Ability and willingness to complete and adhere to survey questions and responses throughout study duration.\n\nExclusion Criteria:\n\n* Pregnancy\n* Ureteric injury during ureteroscopy (PULS ≥ Grade 2)\n* Evidence of ureteral stricture\n* Anatomical abnormalities (e.g., solitary, horseshoe, fused crossed ectopia, pelvic kidney, urinary diversion)\n* Known planned secondary or staged procedure\n* Indwelling nephrostomy tube\n* Bilateral ureteroscopy",{"count":472,"type":20},184,[23],"The study is being completed to compare patient reported outcomes for stent omission vs. placement after using a ureteral access sheath for uncomplicated ureteroscopy.\n\nParticipants that consent for the study will complete baseline PRO questionnaires. A UAS will be used during surgery, and the size left to the discretion of the surgeon. At the end of the procedure, the urologist will evaluate the ureter for iatrogenic injury, and the ureter will be graded using the Post Ureteroscopic Lesion Scale (PULS). Patients assessed with PULS 0 and PULS 1 will meet 2nd stage eligibility and will be randomized 1:1 to either stent omission or stent placement. When a stent is placed, the stent type and decision to leave a string (tether) will be at the operating urologist's discretion.\n\nHypothesis:\n\n\\- stent omission arm will be non-inferior to stent placement in Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference and Pain Intensity, and have lower 30-day healthcare utilization.",[26,476],"Ureteral Stone",[478,479,480,481],"Ureteral stent","Ureteroscopy and lithotripsy","Surveys","Quality of life","2025-12-08",{"date":456,"type":31},{"date":485,"type":31},"2025-09-24",{"date":487,"type":20},"2026-10",{"name":489,"class":38},"University of Michigan",{"id":491,"slug":492,"hasResults":12,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":4,"eligibilityCriteria":496,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":497,"targetDuration":4,"studyType":21,"phases":499,"briefSummary":500,"conditions":501,"keywords":502,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":39},"100611301","outcomes-of-using-fans-with-furs-in-ttt-of-lower-calyceal-stones-100611301","NCT07238803","Outcomes of Using FANS With FURS in TTT of Lower Calyceal Stones.","Outcomes of Using Flexible and Navigable Suction Sheath With Flexible Ureteroscopy in Treatment of Lower Calyceal Stones: A Prospective Study","Inclusion Criteria:\n\n1. Adult patients ≥ 18 years old.\n2. Patients with lower calyceal stones scheduled for FURS.\n\nExclusion Criteria:\n\n1. patients with active urinary tract infections.\n2. Patients with renal and ureteric anomalies.\n3. patients with coagulopathy\n4. patients who are refusing to participate.",{"count":498,"type":20},33,[23],"The aim of this study is to evaluate and assess the outcomes of flexible ureteroscopy (FURS) with flexible and navigable suction UAS (FANS) in the treatment of lower calyceal stones.",[26,160],[503],"Flexible Ureteroscopy","2025-11-18",{"date":506,"type":31},"2025-11-20",{"date":508,"type":31},"2024-12-01",{"date":510,"type":20},"2026-02-01",{"name":512,"class":513},"Zagazig University","OTHER_GOV",{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":520,"eligibilityCriteria":521,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":522,"enrollmentInfo":523,"targetDuration":4,"studyType":21,"phases":525,"briefSummary":526,"conditions":527,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":528,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":534,"locationsCount":536},"100509709","phase-3-impact-of-forced-diuresis-on-the-residual-fragment-rate-after-flexible-ureteroscopy-for-destruction-of-kidney-stones-with-laser-100509709","NCT05916963","Impact of Forced Diuresis on the Residual Fragment Rate After Flexible Ureteroscopy for Destruction of Kidney Stones With Laser","FIRESTONES : Impact of Forced Diuresis on the Residual Fragment Rate After Flexible Ureteroscopy for Destruction of Kidney Stones With Laser: a Randomized Controlled Two-parallel Group Multicenter Trial With Blinding Evaluation","FIREStones","Inclusion Criteria:\n\n* Patients ≥ 18 years old and \\\u003C 80 years old\n* With the need to perform a flexible ureteroscopy with destruction of the kidney stones with laser\n* Participants covered by or entitled to social security\n* Written informed consent obtained from the participant\n* Ability for participant to comply with the requirements of the study\n\nExclusion Criteria:\n\n* Persons covered by articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons: pregnant women, parturients, nursing mothers, persons deprived of their liberty by judicial or administrative decision, minors, and persons subject to a legal protection measure: guardianship or trusteeship)\n* Contra-indication to Furosemide:\n\n  * Hyper-sensitivity to the active substance or one of the excipients\n  * Hyper-sensitivity to Sulfonamide\n  * Renal failure with oligo-anuria refractory to Furosemide\n  * Hypokalemia \\\u003C 3,5 mmol\u002FL\n  * Severe hyponatremia\n  * Hypovolemia with or without hypotension or dehydration\n  * Ongoing hepatitis, hepatic insufficiency severe and hepatic encephalopathy\n* Patient having Furosemide as usual treatment\n* Patient requiring an injection of Aminoside or Vancomycin before or during the procedure\n* Participation in other interventional research with an investigational drug or medical device","80 Years",{"count":524,"type":20},374,[202],"In view of the positive results of the numerous studies conducted on forced diuresis after extra-corporeal lithotripsy, the investigators chose to evaluate forced diuresis by injection of Furosemide associated with intravenous hydration, which has never before been the subject of a specific analysis.",[26],{"date":529,"type":31},"2025-11-24",{"date":531,"type":31},"2024-01-04",{"date":533,"type":20},"2026-04-03",{"name":535,"class":38},"University Hospital, Tours",9,{"id":538,"slug":539,"hasResults":12,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":4,"eligibilityCriteria":543,"healthyVolunteers":153,"sex":16,"minAge":17,"maxAge":154,"enrollmentInfo":544,"targetDuration":4,"studyType":545,"phases":4,"briefSummary":546,"conditions":547,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":39},"100549608","kidney-stone-inflammation-100549608","NCT06436235","Kidney Stone Inflammation","Inflammation and Insulin Resistance in Kidney Stone Patients","Inclusion Criteria:\n\n* Stone formers:\n* Age 18-70\n* History of at least one calcium-based kidney stone\n* Healthy Controls:\n* Age 18-70\n* No history of kidney stone or family history of kidney stones\n\nExclusion Criteria (for both groups):\n\n* History of primarily uric acid\n* Cysteine, or struvite stones\n* History of diabetes or impaired glucose tolerance\n* Previous thiazide use\n* Anyone on a medication that cannot be stopped that may affect urine composition\n* Previous bariatric surgery or ileostomy\n* Primary hyperparathyroidism and elevated serum calcium.",{"count":183,"type":20},"OBSERVATIONAL","This observational study aims to look at the connections between kidney stones, insulin resistance, and inflammation. The researchers hypothesize that people who form calcium kidney stones and have insulin resistance may have higher levels of inflammation because they have more visceral fat (fat around the abdominal organs).\n\nThe study will recruit 20 people who have had calcium kidney stones but don't have diabetes, and 20 healthy people who haven't had kidney stones. All the participants will come to the research center at the University of Chicago Medicine. Participants will have a dual-energy X-ray absorptiometry (DEXA) scan to measure their visceral fat, and give blood and urine samples. The blood will be tested for insulin resistance, inflammatory markers, and other metabolic factors. The urine will be analyzed for substances that increase kidney stone risk.\n\nThe main goal is to see if the kidney stone formers with insulin resistance have more visceral fat compared to those without insulin resistance and the healthy participants. The researchers will also compare inflammatory marker levels between groups, and look at how visceral fat, inflammatory markers, insulin resistance, and urine stone risk factors are related.\n\nThe findings may help explain how kidney stones are connected to metabolic conditions like diabetes and cardiovascular disease. Researchers hope this information will help identify stone formers at risk early and develop preventive treatments in the future.",[26,548],"Stone, Kidney","2025-10-10",{"date":551,"type":31},"2025-10-14",{"date":553,"type":31},"2024-06-30",{"date":555,"type":20},"2026-08-01",{"name":420,"class":38},{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":4,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":522,"enrollmentInfo":564,"targetDuration":4,"studyType":21,"phases":566,"briefSummary":567,"conditions":568,"keywords":569,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":573,"lastUpdatePostDateStruct":574,"startDateStruct":576,"completionDateStruct":577,"leadSponsor":579,"locationsCount":39},"100598473","a-single-center-clinical-study-on-the-efficacy-and-safety-of-visor-100598473","NCT07071948","A Single-Center Clinical Study on the Efficacy and Safety of VISOR","A Single-Center Clinical Study on the Efficacy and Safety of Vortex Intelligence Stone Optimized Removal (VISOR)","Inclusion Criteria:\n\n1. Patients with upper urinary tract calculi, where the maximum diameter of a single calculus or the cumulative diameter of multiple calculi is 1-3 cm\n2. Patients who choose to undergo \"flexible ureteroscopic holmium laser lithotripsy\"\n3. Aged 18-80 years, regardless of gender\n4. Subjects without mental illness or language dysfunction, who can understand the details of this study and sign the informed consent form\n\nExclusion Criteria:\n\n1. Patients with ureteral stricture or a history of ureteral stricture\n2. Patients with a history of open renal and\u002For ureteral surgery or laparoscopic surgery\n3. Fever (body temperature ≥ 38℃) due to urinary tract infection or other reasons within one week before surgery\n4. Pregnant women, lactating women, or women who are in the menstrual period\n5. ASA classification \\> Grade 3: patients with severe systemic diseases, heart diseases, pulmonary insufficiency, and failure of important organ functions, etc., who cannot tolerate anesthesia or surgery\n6. Patients with anatomical malformations such as polycystic kidney, horseshoe kidney, and ectopic kidney\n7. Patients with abnormal coagulation function (e.g., international normalized ratio (INR) \\> 1.5 or platelet count \\\u003C 80 × 10⁹\u002FL)\n8. Patients with failed sheath placement during surgery",{"count":565,"type":20},20,[23],"Goal of this trial:\n\nTo test a new tool called VISOR in adults (aged 18-80) with 1-3 cm kidney or ureter stones. We want to see:\n\n1. If it's safe and works well\n2. If its built-in features (flushing\u002Fsuction, pressure control, and stone-breaking\u002Fremoval) help clear stones better while keeping surgery safe.\n\nMain questions:\n\n1. Can the VISOR clear stones successfully (with fragments \\\u003C4 mm left) for at least 9 out of every 10 people within 24 hours after surgery?\n2. Will serious problems (like severe infections or ureteral injuries) happen to no more than 1 in 20 people (5%)?\n3. Can the device keep pressure inside the kidney below 30 mmHg (a safe level) during the entire surgery?\n\nWhat participants will do:\n\nHave stone removal surgery using VISOR (breaks and removes stones at the same time).\n\nGet a CT scan within 24 hours after surgery to check if stones are cleared.\n\nReturn 4 weeks (±1 week) after surgery for:\n\nAn imaging test (CT or ultrasound)\n\nA check for any health problems related to the surgery.",[161,26],[570,115,571,572],"urolithiasis","stone free rate","VISOR","2025-09-22",{"date":575,"type":31},"2025-09-26",{"date":235,"type":31},{"date":578,"type":20},"2027-02-28",{"name":580,"class":38},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":586,"acronym":4,"eligibilityCriteria":587,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":154,"enrollmentInfo":588,"targetDuration":4,"studyType":21,"phases":590,"briefSummary":591,"conditions":592,"keywords":594,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":605,"locationsCount":39},"100466612","gi-oxalate-absorption-100466612","NCT05356000","GI Oxalate Absorption","Determine the Contribution of Paracellular GI Oxalate Absorption in Obese and Roux-en-Y Gastric Bypass Kidney Stone Patients","Inclusion Criteria:\n\nPost-Roux-en-Y gastric bypass stone formers:\n\n* Age 18-70\n* Previous history of Roux-en-Y gastric bypass\n* History of at least one calcium-based kidney stone after surgery\n* Pre-protocol urine oxalate above the lab normal range (50mg\u002Fday)\n\nObese stone formers:\n\n* Age 18-70\n* Body mass index (BMI) \\>=30kg\u002Fm2\n* History of at least one calcium-based kidney stone\n* Pre-protocol urine oxalate above the lab normal range (50mg\u002Fday)\n\nNon-obese stone formers:\n\n* Age 18-70, BMI between 18.5-29.9 kg\u002Fm2\n* History of at least one calcium-based kidney stone\n\nExclusion Criteria:\n\nPost-Roux-en-Y gastric bypass stone formers:\n\n* History of colon resection (partial or complete)\n* History of duodenal switch bowel surgery\n* History of ileal-jejunal bypass surgery\n* History of primarily uric acid, cysteine, or struvite stones\n\nObese and non-obese stone formers:\n\n* History of bowel surgery\n* History of colon resection\n* History of inflammatory bowel disease (Crohn's disease, Ulcerative Colitis)\n* History of primarily uric acid, cysteine, or struvite stones",{"count":589,"type":20},30,[23],"This study aims to learn more about how oxalate, a compound found in many foods, may affect a person's chances of forming kidney stones. Active participation in this study will last for around one week.\n\nFor the first two days, subjects will be asked to eat a special diet at home. From Days 3-5, they will eat special meals delivered to their home from a research clinic at the University of Chicago. They will also collect 24-hour urine samples at home on Days 4 and 5. On Day 6, they will come in to the research clinic at the University of Chicago in Hyde Park, where they will spend most of the day. They will receive a special liquid that contains oxalate, and we will have them eat a specially prepared breakfast that is low in oxalate and citrate.",[593,26],"Bariatric Surgery Candidate",[595,596,597],"Roux-en-Y Gastric Bypass","RYGB","Oxalate","2025-08-14",{"date":600,"type":31},"2025-08-19",{"date":602,"type":31},"2023-01-25",{"date":604,"type":20},"2026-08-02",{"name":420,"class":38}]